COL6A2

Across TCGA pan-cancer cohorts, COL6A2 mass-spec protein differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of COL6A2’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where COL6A2 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types COL6A2 is over-expressed in tumor, although a few such as COAD and LUAD show the opposite, repressed pattern.

CCRCC, COAD, and LUAD are the cancer types where COL6A2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in COL6A2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	All	IV	+0.629	<.001	12	view →
COAD	Male	III,IV	−1.444	<.001	11	view →
LUAD	Female	II,III,IV	−0.842	<.001	9	view →
LSCC	Male	II,III,IV	−0.908	<.001	8	view →
HNSC	All	II,III,IV	−0.340	<.001	6	view →
PDAC	Female	All	+0.360	.004	4	view →
OV	All	All	−1.098	.003	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

COL6A2–CCRCC

Open the CCRCC breakdown →